Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders

Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.

cGMP-dependent 3',5'-cyclic phosphodiesterase

Cyclic GMP-stimulated phosphodiesterase,cGSPDE

Baculovirus expression vector pFastBac1-HM

HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS U VALUES : WITH TLS ADDED

cGMP-dependent 3',5'-cyclic phosphodiesterase (E.C.3.1.4.17)

Inhibitor, Phosphodiesterase, Brain-Pentrating, Cognitive Disorders, HYDROLASE-HYDROLASE INHIBITOR complex